Interactive viz shows ‘09 dip in Argentinean trial sector

By Nick Taylor

- Last updated on GMT

Related tags: South america

Clinical trials initiated in Argentina slumped year-on-year by 37 per cent in 2009. Outsourcing-Pharma presents this, and other shifts in the South American clinical trials market over the past decade, in an interactive visualisation.

The decline in trials in 2009 in Argentina, and many other South American nations, coincides with a widespread downturn in the pharmaceutical and contract research sectors. Total trials initiated in South America fell from 938 in 2008 to 849 in 2009.

Brazil and Peru were the only South American countries where clinical trial initiation continued to increase in 2009. With 443 trials initiated in 2009, up from 408 a year previously, Brazil is the dominant presence in the South American trials market.

Despite clinical trial initiation falling year-on-year from 108 to 91 in 2009, Chile still had the most studies per 1m in population.

Between 2004 and 2005 there is a large leap in the number of clinical trials initiated. This change is underpinned by a number of factors related to submission of information to which are discussed here​ .

Data was collated from by Outsourcing-Pharma. The datasets used in these visualisations can be viewed here.

Below is a heat map showing clinical trial initiation per 1m people. Pressing play animates the changes in clinical trial concentration which took place in South American countries from 2000 to 2009.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more